How do you choose between regorafenib or TAS-102 in patients with metastatic colorectal carcinoma that has progressed on all prior 5-FU based regimens and anti-EGFR therapy?

Topics: Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer

Answer from: Medical Oncologist at Academic Institution

Despite their FDA approval, both TAS-102 and regorafenib are equally marginal drugs in terms of their efficacy. In the world of GI Oncology, there are those of us who do and do not treat HCC; those who do have experience with sorafenib and regorafenib and find both drugs to be "tolerable". On the ot...

Comments

Medical Oncologist at St Lukes Cancer Care Assocs
I could go either way based on patient's character...

Answer from: Medical Oncologist at Community Practice

It is worth noting the Rego Nivo data presented at ASCO 2019 showed promising preliminary activity in MSS colorectal cancer in a Japanese population of patients. Patients in the dose-escalation cohort were given 80 mg, 120 mg, or 160 mg of regorafenib once per day for 21 days with 7-day gaps in the ...

Related Questions